Sertraline‐Associated Riboflavin‐Responsive Lipid Storage Myopathy: Report of Two Case

Although riboflavin therapy is often reserved for genetically confirmed patients, our findings support its efficacy in sertraline-associated, genetically negative MADD. These cases underscore the importance of recognizing medication-associated metabolic myopathies and the potential for targeted riboflavin therapy.